6.02
price down icon0.82%   -0.05
after-market アフターアワーズ: 6.02
loading
前日終値:
$6.07
開ける:
$6.03
24時間の取引高:
671.31K
Relative Volume:
0.33
時価総額:
$575.26M
収益:
-
当期純損益:
$-29.07M
株価収益率:
-20.76
EPS:
-0.29
ネットキャッシュフロー:
$-31.85M
1週間 パフォーマンス:
+1.18%
1か月 パフォーマンス:
-6.96%
6か月 パフォーマンス:
+79.70%
1年 パフォーマンス:
+112.35%
1日の値動き範囲:
Value
$5.95
$6.16
1週間の範囲:
Value
$5.88
$6.39
52週間の値動き範囲:
Value
$2.30
$7.39

Trevi Therapeutics Inc Stock (TRVI) Company Profile

Name
名前
Trevi Therapeutics Inc
Name
セクター
Healthcare (1155)
Name
電話
203-304-2499
Name
住所
195 CHURCH STREET, NEW HAVEN, CT
Name
職員
26
Name
Twitter
@TreviThera
Name
次回の収益日
2025-03-18
Name
最新のSEC提出書
Name
TRVI's Discussions on Twitter

TRVI を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
TRVI
Trevi Therapeutics Inc
6.02 575.26M 0 -29.07M -31.85M -0.29
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-03-10 繰り返されました Needham Buy
2025-03-10 アップグレード Raymond James Outperform → Strong Buy
2024-12-12 繰り返されました H.C. Wainwright Buy
2024-09-09 再開されました Leerink Partners Outperform
2024-08-30 開始されました H.C. Wainwright Buy
2024-08-30 開始されました Raymond James Outperform
2024-06-13 開始されました Rodman & Renshaw Buy
2023-04-12 開始されました B. Riley Securities Buy
2022-11-22 開始されました SVB Leerink Outperform
2019-06-03 開始されました BMO Capital Markets Outperform
2019-06-03 開始されました Needham Buy
2019-06-03 開始されました SVB Leerink Outperform
2019-06-03 開始されました Stifel Buy
すべてを表示

Trevi Therapeutics Inc (TRVI) 最新ニュース

pulisher
Apr 14, 2025

12,000 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Acquired by Raymond James Financial Inc. - Defense World

Apr 14, 2025
pulisher
Apr 14, 2025

American Century Companies Inc. Buys 24,153 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Apr 14, 2025
pulisher
Apr 12, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Rating of “Buy” by Analysts - Defense World

Apr 12, 2025
pulisher
Apr 10, 2025

Trevi Therapeutics Sees Unusually Large Options Volume (NASDAQ:TRVI) - Defense World

Apr 10, 2025
pulisher
Apr 09, 2025

Trevi Therapeutics (NASDAQ:TRVI) Given Buy Rating at Needham & Company LLC - Defense World

Apr 09, 2025
pulisher
Apr 07, 2025

Trevi Therapeutics at 24th Annual Needham: Strategic Advances in Cough Treatments - Investing.com Canada

Apr 07, 2025
pulisher
Apr 04, 2025

Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - Seeking Alpha

Apr 04, 2025
pulisher
Apr 04, 2025

Prurigo Nodularis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therapeutics - The Globe and Mail

Apr 04, 2025
pulisher
Apr 03, 2025

Trevi Therapeutics to Participate in Upcoming April Investor Conferences - The Malaysian Reserve

Apr 03, 2025
pulisher
Apr 03, 2025

Trevi's Game-Changing Chronic Cough Treatment Takes Center Stage at 3 Major Healthcare Conferences - Stock Titan

Apr 03, 2025
pulisher
Apr 03, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Sees Significant Growth in Short Interest - Defense World

Apr 03, 2025
pulisher
Apr 01, 2025

Charles Schwab Investment Management Inc. Has $713,000 Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones - Proactive financial news

Mar 31, 2025
pulisher
Mar 28, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Acquired by Bank of New York Mellon Corp - Defense World

Mar 28, 2025
pulisher
Mar 26, 2025

Trevi therapeutics chief scientific officer Sciascia sells $17,364 in stock By Investing.com - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

Trevi therapeutics chief scientific officer Sciascia sells $17,364 in stock - Investing.com

Mar 26, 2025
pulisher
Mar 25, 2025

Trevi therapeutics CEO Jennifer Good sells $34,624 in stock By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

Trevi therapeutics CEO Jennifer Good sells $34,624 in stock - Investing.com

Mar 25, 2025
pulisher
Mar 22, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 22, 2025
pulisher
Mar 22, 2025

Equities Analysts Offer Predictions for TRVI Q2 Earnings - Defense World

Mar 22, 2025
pulisher
Mar 22, 2025

Q3 EPS Estimate for Trevi Therapeutics Reduced by Analyst - Defense World

Mar 22, 2025
pulisher
Mar 22, 2025

Leerink Partnrs Analysts Boost Earnings Estimates for TRVI - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

HC Wainwright Reiterates “Buy” Rating for Trevi Therapeutics (NASDAQ:TRVI) - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

Trevi Therapeutics (NASDAQ:TRVI) Earns “Buy” Rating from B. Riley - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

D. Boral Capital Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI) - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

Needham & Company LLC Lowers Trevi Therapeutics (NASDAQ:TRVI) Price Target to $24.00 - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

Brokerages Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Price Target at $15.94 - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up Following Better-Than-Expected Earnings - Defense World

Mar 20, 2025
pulisher
Mar 20, 2025

Trevi Therapeutics Stock (TRVI) Surges Over 60% on Promising Trial Results and Q4 Financials - Markets Insider

Mar 20, 2025
pulisher
Mar 20, 2025

Needham & Company LLC Issues Pessimistic Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price - The AM Reporter

Mar 20, 2025
pulisher
Mar 19, 2025

B. Riley Boosts Price Target on Trevi Therapeutics to $20 From $11, Keeps Buy Rating - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

Trevi Therapeutics Inc (TRVI) Q4 2024 Earnings Call Highlights: Navigating Losses and Advancing ... - Yahoo

Mar 19, 2025
pulisher
Mar 19, 2025

Trevi Therapeutics Inc (TRVI) Q4 2024 Earnings Call Highlights: Navigating Losses and Advancing Promising Trials - GuruFocus

Mar 19, 2025
pulisher
Mar 18, 2025

Trevi Therapeutics Advances Haduvio in Clinical Trials - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Earnings call transcript: Trevi Therapeutics Q4 2024 reports mixed results - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Trevi Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates - PR Newswire

Mar 18, 2025
pulisher
Mar 16, 2025

TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study - MSN

Mar 16, 2025
pulisher
Mar 16, 2025

Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) large institutional owners must be happy as stock continues to impress, up 57% over the past week - Yahoo Finance

Mar 16, 2025
pulisher
Mar 14, 2025

Trevi Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView

Mar 14, 2025
pulisher
Mar 14, 2025

HC Wainwright Analysts Increase Earnings Estimates for TRVI - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Stock Traders Purchase Large Volume of Trevi Therapeutics Call Options (NASDAQ:TRVI) - The AM Reporter

Mar 13, 2025
pulisher
Mar 13, 2025

Trevi Therapeutics’ chief commercial officer sells $548,877 in stock - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Trevi Therapeutics’ chief commercial officer sells $548,877 in stock By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 12, 2025

Biotech Alert: Searches spiking for these stocks today - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Investors Buy High Volume of Trevi Therapeutics Call Options (NASDAQ:TRVI) - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $20.00 at Oppenheimer - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Trevi Therapeutics (NASDAQ:TRVI) Hits New 52-Week High After Analyst Upgrade - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Trevi Therapeutics (TRVI) Projected to Post Quarterly Earnings on Wednesday - Defense World

Mar 12, 2025

Trevi Therapeutics Inc (TRVI) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
大文字化:     |  ボリューム (24 時間):